Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
ST. LOUIS, May 19, 2017 -- GeneriCo, LLC (GeneriCo), a global specialty generic drug company, today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office ruled in favor of its petition for Inter Partes Review (“IPR”) of the Valeant Pharmaceuticals International, Inc. U.S. Patent 8,865,688 (the ‘688 Patent). The PTAB’s decision invalidates all of the disputed claims of the '688 Patent that previously provided Apriso® (extended-release capsules containing 0.375g mesalamine as a locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis in adults) FDA Orange Book exclusivity through May 1, 2030.
“Along with our IPR partner Flat Line Capital, LLC, we are pleased that the PTAB has decided to invalidate all the disputed claims of the ‘688 Patent,” said Daniel Thompson, GeneriCo President and CEO. “While more remains to be done, this is a significant step forward to lowering prescription drug costs for patients and healthcare providers in the U.S. system.”
Kevin Barnes, Principal of Flat Line Capital, LLC added, “We believe this successful IPR outcome further validates our leadership in pharmaceutical intellectual property disputes and the effectiveness of our platform.”
About GeneriCo, LLC
GeneriCo, LLC is a generic pharmaceutical company focused on developing and marketing niche, high barrier drugs in the United States. The Company employs a four-pillar collaboration business strategy capitalizing on management’s deep industry knowledge and experience to collaborate with partners on the discovery, formulation, development and manufacture of generic drugs. The Company expects its 1st internally-developed ANDA to be filed in 2017.
Contact: Daniel Thompson, President and CEO Phone Number: 1.314.330.0800 Email: [email protected] www.genericopharma.com
